Trabectedin
Trabectedin (Yondelis) | Cancer information
Trabectedin works by sticking to the DNA Open a glossary item in cells and damaging it. This stops the cancer cells growing and multiplying.
YONDELIS (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior ...
It is sold by Pharma Mar S.A. and Johnson and Johnson. It is approved for use in the European Union, Russia, South Korea and the United States. The European ...
Trabectedin (intravenous route) - Mayo Clinic
Trabectedin injection is used to treat certain types of cancer, including liposarcoma or leiomyosarcoma that cannot be treated with surgery.
Trabectedin - LiverTox - NCBI Bookshelf
Trabectedin is a natural product derived from the Caribbean sea squirt which has antineoplastic activity and is used to treat soft tissue ...
Trabectedin and Doxorubicin Effective for Leiomyosarcoma - NCI
Combining trabectedin (Yondelis) with doxorubicin helps people with leiomyosarcoma live longer than doxorubicin alone, new clinical trial ...
Trabectedin: Uses, Interactions, Mechanism of Action - DrugBank
Indicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy.
trabectedin - Cancer Care Ontario
trabectedin · Grade 3 or 4 LFT elevations are common, usually occur in the first week, and recover prior to the next planned dose. · CPK elevations are common; ...
Trabectedin Injection: MedlinePlus Drug Information
Trabectedin is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in your body.
Trabectedin and its potential in the treatment of soft tissue sarcoma
Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair machinery.
Trabectedin - an overview | ScienceDirect Topics
Mechanism of action. Trabectedin is an alkylating agent that binds DNA at the N2 position of guanine promoting degradation of RNA polymerase and generating DNA ...
FDA Approves Trabectedin for Sarcoma - NCI
The FDA has approved trabectedin for patients with advanced liposarcoma and leiomyosarcoma whose cancer has progressed after prior ...
Trabectedin - an overview | ScienceDirect Topics
Trabectedin is a tetrahydroisoquinoline molecule that binds to the minor groove of DNA, forming trabectedin-DNA adducts, which bend the DNA toward the major ...
Doxorubicin–Trabectedin with Trabectedin Maintenance in ...
Combination therapy with doxorubicin and trabectedin induction, followed by trabectedin maintenance, was associated with improved overall ...
Yondelis (trabectedin) dosing, indications, interactions ... - Medscape
Indicated for unresectable or metastatic liposarcoma or leiomyosarcoma in patients who have received a prior anthracycline-containing regimen.
Trabectedin, a drug acting on both cancer cells and the tumour ...
Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination ...
Trabectedin - Macmillan Cancer Support
Common side effects · Risk of infection · Bruising and bleeding · Anaemia (low number of red blood cells) · Feeling tired · Difficulty sleeping (insomnia).
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
The available data indicate that trabectedin is a minor groove binder, able to induce DNA damage that will finally alter the normal function of DNA repair and ...
Trabectedin monotherapy after standard chemotherapy versus best ...
Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open- ...
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic ...
In the final analysis of PFS, trabectedin administration resulted in a 45% reduction in the risk of disease progression or death compared with ...
Trabectedin
MedicationTrabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.